• The universality of the ambroxol effects in the pathology therapy of the respiratory diseases among children: an inhaled forms priorit
To content

The universality of the ambroxol effects in the pathology therapy of the respiratory diseases among children: an inhaled forms priorit

SOVREMENNAYA PEDIATRIYA.2014.4(60):106110; doi 10.15574/SP.2014.60.106 

The universality of the ambroxol effects in the pathology therapy of the respiratory diseases among children: an inhaled forms priorit

Оvcharenko L. S., Vertegel А. А., Аndrienko Т. G., Zhihareva N. V., Samohin I. V., Doroshenko S. V. 
SU «Zaporizhska Medical Academy of Postgraduate Education, Ministry of Health of Ukraine », Zaporizhia, Ukraine

The ambroxol properties had been projected and its applications in the therapy of the respiratory diseases among children.

Key words: children, bronchitis, ambroxol, inhalations, nebulizer.

1. Антипкін ЮГ, Резніченко ЮГ, Леженко ГО. 2010. Пульмонологія дитячого віку. Навч-метод посіб. Запоріжжя, Просвіта: 279.

2. Ермилова ЕВ, Лобеева НА, Радциг ЕЮ. 2008. Хронический кашель у детей. РМЖ. 16;3: 139—144.

3. Овчаренко ЛС, Шамрай ІВ. 2010. Вплив амброксолу на вміст деяких нейропептидів у сироватці крові дітей, хворих на рекурентні форми бронхітів. Совр педиатрия. 4: 224.

4. Овчаренко ЛС, Шамрай ІВ, Редько ІІ та ін. 2012. Сироватковий рівень деяких нейромедіаторів у дітей з перинатальним ураженням центральної нервової системи залежно від гостроти запального процесу в бронхах. Совр педиатрия. 3: 132—134.

5. Антипкін ЮГ, Марушко ЮВ, Крамарев СО та ін. 2011. Фармакотерапія захворювань органів дихання у дітей. Приватна друкарня ФО-П Петришин Г. М.: 496.

6. Lee CS, Jang YY, Song JS et al. 2002. Ambroxol inhibits peroxynitrite-induced damage of a a1-antiproteinase and free radical production in activated phаgocytic cells. Pharmacol. Toxicol. 91: 140—149.

7. Yang B, Yao DF, Ohuchi M et al. 2002. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 19: 952—958.

8. Seifart C, Clostermann U, Seifart U et al. 2005. Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol. 203: 27—35.

9. Jang YY, Song JH, Shin YK et al. 2003. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol. 92: 173—179.

10. Seagravel JC,. Albrecht HH, Hill DB et al. 2012. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human trachealbronchial cells. Respiratory Research. 13: 98.

11. Gupta PR. 2010. Ambroxol — Resurgence of an old molecule as an anti-in-flammatory agent in chronic obstructive airway diseases. Lung India. 27(2): 46—48. http://dx.doi.org/10.4103/0970-2113.63603; PMid:20616932 PMCid:PMC2893422

12. Hu Q, Lian JM, Li JQ. 2006. Efficacy of intravenous or atomizing ambroxol for prevention of respiratory distress syndrome in preterm infants. Zhongguo Dang Dai Er Ke Za Zhi. 8(4): 301—303.

13. Ren Y, Yu C, Meng K, Tang X. 2008. Influence of formulation and preparation process on ambroxol hydrochloride dry powder inhalation characteristics and aerosolization properties. Drug Dev Ind Pharm. 34(9): 984—991. http://dx.doi.org/10.1080/03639040802154913; PMid:18800258

14. Su X, Wang L, Song Y, Bai C. 2004. Inhibition of inflammatory responses by ambroxol: A mucolyte agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 30: 133—140.

15. Malerba M, Ragnoli B. 2008. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 4(8): 1119—1129. http://dx.doi.org/10.1517/17425255.4.8.1119; PMid:18680446

16. Ren YC, Wang L, He HB, Tang X. 2009. Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat. J Pharm Sci. 98(5): 1797—1803. http://dx.doi.org/10.1002/jps.21529; PMid:18837427

17. Qian X-S. 2010. The Efficacy about Nebulized Inhalation of Different Ways of Ambroxol Treatment of Patients with Acute Exacerbation of Chronic Bronchitis. Guide of China Medicine. 18: 18.

18. Rogers DF. 2007. Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respiratory Care. 52(9): 1176—1197.

19. Tang HP, Li JC. 2006. Atomization inhalation of ambroxol as an auxiliary therapy for severe pneumonia in neonates. Zhongguo Dang Dai Er Ke Za Zhi. 8(3): 249—250.

20. Jahnz-Rozyk K, Kucharczyk A, Chciatowski A, Ptusa T. 2001. The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients. Pol Merkur Lekarski. 11(63): 239—243.

21. Gao X, Huang Y, Han Y et al. 2011. The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch Med Sci. 7(3): 405—413. http://dx.doi.org/10.5114/aoms.2011.23403; PMid:22312374 PMCid:PMC3258752

22. Liu X-Q, Yuan X, Liu S-J, Liu Y. 2010. To Observe the Efficacy of Aerosol Inhalation with Budesonide, Combivent and Ambroxol for Bronchiolitis. J of Pediatric Pharmacy. 5: 124—128.

23. Zhang L-J, Lin S-Y. 2008. Observation on the effection of nebulized_inhalation of salbutamol and ambroxol in treating bronchiolitis. J of Pediatric Pharmacy. 4: 57—64.